Ferumoxytol增强MRI提高儿童和年轻成人骨转移的检测
一项前瞻性研究的二次分析纳入26例患癌儿童和年轻成人,比较非增强与Ferumoxytol增强全身扩散加权MRI检测骨 marrow 转移。Ferumoxytol增强MRI正常骨髓SNR更低、肿瘤-骨髓对比更高,敏感度96% vs 83%,诊断准确率99% vs 95%。
要点
- Ferumoxytol增强MRI正常骨髓SNR低于非增强MRI,基线P=0.03,化疗后P=0.006。
- Ferumoxytol增强MRI肿瘤-骨髓对比高于非增强MRI,基线P=0.07,化疗后P=0.007。
- Ferumoxytol增强MRI检测骨 marrow 转移敏感度96%(94/98)、准确率99%(293/297)。
核心结论
- 使用Ferumoxytol有助于提高儿童和年轻成人癌症患者骨 marrow 转移的检测。
研究设计与样本
- 前瞻性机构审查委员会批准研究的二次分析,纳入26例儿童和年轻成人(年龄2-25岁,18例男性),于2015年至2020年接受非增强或Ferumoxytol增强全身扩散加权MRI;以18F-FDG PET及随访胸部CT、腹部和盆腔CT、标准(非Ferumoxytol增强)MRI为参考标准。
诊断标准与关键数值
- Ferumoxytol增强MRI检测骨 marrow 转移的敏感度为96%(94/98),诊断准确率为99%(293/297)。
- 非增强MRI检测骨 marrow 转移的敏感度为83%(106/127),诊断准确率为95%(369/390)。
临床应用与阅片要点
- Ferumoxytol增强MRI可提高儿童和年轻成人癌症患者骨 marrow 转移的检测敏感度和诊断准确率。
- Ferumoxytol增强MRI较非增强MRI降低正常骨髓SNR并增加肿瘤-骨髓对比。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate if ferumoxytol can improve the detection of bone marrow metastases at diffusion-weighted (DW) MRI in pediatric and young adult patients with cancer. Materials and Methods In this secondary analysis of a prospective institutional review board-approved study (ClinicalTrials.gov identifier NCT01542879), 26 children and young adults (age range: 2-25 years; 18 males) underwent unenhanced or ferumoxytol-enhanced whole-body DW MRI between 2015 and 2020. Two reviewers determined the presence of bone marrow metastases using a Likert scale. One additional reviewer measured signal-to-noise ratios (SNRs) and tumor-to-bone marrow contrast. Fluorine 18 (18F) fluorodeoxyglucose (FDG) PET and follow-up chest CT, abdominal and pelvic CT, and standard (non-ferumoxytol enhanced) MRI served as the reference standard. Results of different experimental groups were compared using generalized estimation equations, Wilcoxon rank sum test, and Wilcoxon signed rank test. Results The SNR of normal bone marrow was significantly lower at ferumoxytol-enhanced MRI compared with unenhanced MRI at baseline (21.380 ± 19.878 vs 102.621 ± 94.346, respectively; P = .03) and after chemotherapy (20.026 ± 7.664 vs 54.110 ± 48.022, respectively; P = .006). This led to an increased tumor-to-marrow contrast on ferumoxytol-enhanced MRI scans compared with unenhanced MRI scans at baseline (1397.474 ± 938.576 vs 665.364 ± 440.576, respectively; P = .07) and after chemotherapy (1099.205 ± 864.604 vs 500.758 ± 439.975, respectively; P = .007). Accordingly, the sensitivity and diagnostic accuracy for detecting bone marrow metastases were 96% (94 of 98) and 99% (293 of 297), respectively, with the use of ferumoxytol-enhanced MRI compared with 83% (106 of 127) and 95% (369 of 390) with the use of unenhanced MRI. Conclusion Use of ferumoxytol helped improve the detection of bone marrow metastases in children and young adults with cancer. Keywords: Pediatrics, Molecular Imaging-Cancer, Molecular Imaging-Nanoparticles, MR-Diffusion Weighted Imaging, MR Imaging, Skeletal-Appendicular, Skeletal-Axial, Bone Marrow, Comparative Studies, Cancer Imaging, Ferumoxytol, USPIO © RSNA, 2023 ClinicalTrials.gov registration no. NCT01542879 See also the commentary by Holter-Chakrabarty and Glover in this issue.
引用
- Rashidi A, Baratto L, Theruvath AJ, et al. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI. Radiol Imaging Cancer. 2023. PMID: 36999999. doi:10.1148/rycan.220080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。